DGAP-News

PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS DR. DR. IRINA ANTONIJEVIC AND DR. CHRIS TANNER TO THE SUPERVISORY BOARD

DGAP-News: PAION AG / Key word(s): AGM/EGM PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS DR. DR. IRINA ANTONIJEVIC AND DR. CHRIS TANNER TO THE SUPERVISORY BOARD 17.05.2017 / 16:07 The issuer is solely responsible for the content of this announcement. PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS DR. DR. IRINA ANTONIJEVIC AND DR. CHRIS TANNER TO THE SUPERVISORY BOARD

- Agenda items approved with large majority

- Supervisory Board expanded to five members with Dr. Dr. Irina Antonijevic and Dr. Chris Tanner

Aachen (Germany), 17 May 2017 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the resolutions proposed by the Management Board and Supervisory Board were accepted by the Annual General Meeting on 17 May 2017 with large majorities. The results are available on the company's website www.paion.com/media-and-investors/annual-general-meeting.

Dr. Dr. Irina Antonijevic and Dr. Chris Tanner have been elected to the company's Supervisory Board by the Annual General Meeting. This was based on the approval of the Annual General Meeting to increase the number of Supervisory Board members from three to five.

The chairman of the Supervisory Board, Dr Jörg Spiekerkötter, commented: "I am very pleased that we were able to win well-known industry experts with Dr. Dr. Irina Antonijevic and Dr. Chris Tanner as new Supervisory Board members for PAION AG. I look forward to working together with them."

###

About Dr. Dr. Irina Antonijevic

Dr. Dr. Irina Antonijevic joined vasopharm GmbH in 2016 as Chief Medical Officer. She has more than 16 years of drug development experience in different pharmaceutical organizations, with a focus on neuropsychiatric and rare diseases. In her last role at Sanofi Genzyme in Cambridge (MA, USA), she oversaw multiple innovative clinical programs as Global Head Early Development Neurology and Ophthalmology. She completed her medical studies at the Technical University of Munich (1991), received her MD from the Max Planck Institute in Munich (1992) and her PhD from the University of Edinburgh, UK (1995). She completed her residency at the Max Planck Institute of Psychiatry in Munich and received her Venia Legendi from the Charité, Berlin, in 2004. Dr. Dr. Antonijevic has been a regular reviewer for the German Ministry of Research (BMBF) since 2006.